ADZENYS ER Drug Patent Profile

Which patents cover Adzenys Er, and what generic alternatives are available?

Adzenys Er is a drug marketed by Neos Theraps Inc and is included in one NDA. There are three patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ADZENYS ER is amphetamine. There are fifty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adzenys Er

A generic version of ADZENYS ER was approved as amphetamine by ACTAVIS LABS FL INC on June 22^nd, 2023.

Summary for ADZENYS ER

International Patents:	2
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	2
Drug Prices:	Drug price information for ADZENYS ER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADZENYS ER
What excipients (inactive ingredients) are in ADZENYS ER?	ADZENYS ER excipients list
DailyMed Link:	ADZENYS ER at DailyMed

See drug prices for ADZENYS ER

Recent Clinical Trials for ADZENYS ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aytu BioPharma, Inc.	PHASE4
Premier Research Group plc	PHASE4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2

See all ADZENYS ER clinical trials

US Patents and Regulatory Information for ADZENYS ER

ADZENYS ER is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No			Y
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No			Y
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No			Y

International Patents for ADZENYS ER

When does loss-of-exclusivity occur for ADZENYS ER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ADZENYS ER around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622

ADZENYS ER Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for ADZENYS ER?

ADZENYS ER (amphetamine extended-release) is a prescription medication approved for treating Attention Deficit Hyperactivity Disorder (ADHD). Its market depends on several factors:

Competitive Landscape

ADZENYS ER faces competition from established stimulants like Vyvanse (lisdexamfetamine), Adderall XR (amphetamine/dextroamphetamine), and Concerta (methylphenidate). These drugs dominate the ADHD market, with Vyvanse leading in sales and prescriptions.

Market Size

The US ADHD drug market was valued at approximately $4.4 billion in 2022, with stimulants accounting for roughly 70% of the segment. The global ADHD therapeutics market is projected to reach $11 billion by 2027, growing at a compound annual growth rate (CAGR) of 4%. The market is driven by increased diagnosis rates and prescription fills.

Regulatory and Reimbursement Factors

FDA approval in 2019 for ADZENYS ER was followed by gradual adoption. Insurance coverage and formulary placement influence sales volume. Generic competition started to enter the market in 2020, exerting downward pressure on prices.

Prescriber and Patient Adoption

Physician prescribing habits have historically favored well-established brands. The drug's positioning hinges on its dosing flexibility and extended-release profile, appealing to patients seeking sustained symptom control. Patient adherence improves with extended-release formulations.

Pricing Dynamics

Average wholesale price (AWP) for ADZENYS ER ranges between $350 and $450 per month. Reimbursement rates from insurers and pharmacy benefit managers (PBMs) significantly affect out-of-pocket costs for patients and impact market penetration.

Outlook

Market penetration remains limited relative to competitors, partly due to its late entry and lack of unique differentiators. Growth prospects depend on expanding indications, improving formulary access, and clinical data demonstrating superior efficacy or tolerability.

---

What Is the Financial Trajectory for ADZENYS ER?

Revenue Trends

Since its approval in 2019, ADZENYS ER has seen gradual revenue growth:

Year	Estimated US Sales (USD millions)	Notes
2020	20	Limited market penetration
2021	35	Increased prescriber awareness
2022	50	Competition intensifies

These figures reflect estimates based on prescription volume data and wholesale acquisition costs (WAC).

Market Share

ADZENYS ER holds less than 1% of the overall stimulant ADHD market. Leading brands like Vyvanse and Adderall XR control over 70% combined. Its share remains marginal, with room for modest growth.

Cost Structure

Manufacturing costs for extended-release amphetamine formulations are approximately 20% of price. Marketing and sales expenses are relatively low given limited promotion efforts. Patent expiration or exclusivity impacts future profit margins.

Investment and Development Outlook

Multiple generics have entered the market, eroding revenue potential. Additional formulations or indications could extend lifecycle value. Partnering with large pharma for broader distribution could improve sales trajectory.

Risks and Opportunities

Key risks include:

• Price erosion due to generics
• Competition from new formulations and non-stimulant therapies
• Changing regulatory guidelines

Opportunities are:

• Pediatric and adult ADHD indications expansion
• Combination therapies
• Entry into international markets where ADHD diagnosis rises

Financial Forecast

Projected revenue for 2023-2025 remains conservative, with estimates in the $60-$80 million range annually, assuming gradual market adoption and no significant new competition.

---

Key Takeaways

• ADZENYS ER operates within a highly competitive stimulant market with dominant existing brands.
• Its revenue growth remains constrained by limited market share and aggressive generic competition.
• Price sensitivity and formulary access are critical factors influencing sales.
• Long-term prospects depend on product differentiation, new indications, and strategic partnerships.
• Financial impact is modest, with annual revenues forecasted under $100 million unless significant market expansion occurs.

---

FAQs

1. How does ADZENYS ER compare pricing-wise to competitors?
It is priced similarly to other extended-release stimulants, with monthly costs around $350–$450. Brands like Vyvanse are generally priced higher.

2. What are the main barriers to growth for ADZENYS ER?
Generic competition and limited formulary placement restrict sales. Additionally, prescriber familiarity favors established brands.

3. Are there ongoing clinical trials or new indications for ADZENYS ER?
No publicly announced additional indications are underway. Future trials could focus on adult ADHD or non-stimulant approvals.

4. What share of the ADHD market does ADZENYS ER hold?
Less than 1% of the stimulant ADHD market, with room for marginal growth.

5. What is the outlook for generics impacting ADZENYS ER?
Generic versions dramatically reduce brand revenues; the trend is expected to continue, pressuring profit margins.

---

Sources:
[1] IQVIA. "2019–2022 US ADHD Medication Market Data."
[2] Grand View Research. "ADHD Therapeutics Market Size, Share & Trends."
[3] FDA New Drug Approvals Database.
[4] Company filings and investor presentations.